Empagliflozin is prescribed in combination with dietary and exercise measures, and sometimes in conjunction with other medications, to reduce elevated blood sugar levels in individuals diagnosed with type 2 diabetes. Type 2 diabetes is a medical condition characterized by elevated blood sugar levels due to the body’s impaired production or utilization of insulin. Empagliflozin belongs to a category of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. Its primary mechanism of action involves promoting the excretion of excess glucose through the kidneys into the urine. It is essential to note that Empagliflozin is not intended for the treatment of type 1 diabetes, a condition in which the body does not produce insulin and therefore cannot regulate blood sugar levels, or for diabetic ketoacidosis, a severe condition that may develop when high blood sugar remains untreated.